@misc{oai:niigata-u.repo.nii.ac.jp:00005999,
 author = {Tanaka, Tomohiro},
 month = {Mar},
 note = {The adoptive transfer of effector T cells combined with lymphodepletion has demonstrated promising antitumor effects in mice and humans, although the availability of tumor-specific T cells is limited. We and others have also demonstrated that the transfer of polyclonal naïve T cells induces tumor-specific effector T cells and enhances antitumor immunity after lymphodepletion. Because tumors have been demonstrated to induce immunosuppressive networks and regulate the function of T cells, obtaining a sufficient number of fully functional naive T cells that are able to differentiate into tumor-specific effector T cells remains difficult. To establish culture methods to obtain a large number of polyclonal T cells that are capable of differentiating into tumor-specific effector T cells, naïve T cells were activated with anti-CD3 mAbs in vitro. These cells were stimulated with IL-2 and IL-7 for the CD8 subset or with IL-7 and IL-23 for the CD4 subset. Transfer of these hyperexpanded T cells after lymphodepletion showed significant antitumor efficacy, and tumor-specific effector T cells were primed from these expanded T cells in tumor-bearing hosts. Moreover, these ex vivoÐ expanded T cells maintained T cell receptor diversity and showed long-term persistence of memory against specific tumors. Further analyses revealed that combination therapy consisting of vaccination with dendritic cells that were co-cultured with irradiated whole tumor cells and the transfer of ex vivoÐexpanded T cells significantly enhanced antitumor immunity. These results indicate that the transfer of ex vivoÐexpanded polyclonal T cells can be combined with other immunotherapies and augment antitumor effects., 学位の種類: 博士（医学）. 報告番号: 甲第4401号. 学位記番号: 新大院博（医）甲第800号. 学位授与年月日: 平成30年3月23日, PLOS ONE. 2017.  12(8), e0183976., 新大院博（医）甲第800号},
 title = {Transfer of in vitro-expanded naive T cells after lymphodepletion enhances antitumor immunity through the induction of polyclonal antitumor effector T cells},
 year = {2018}
}